title: [Preclinical features of anti-angiogenesis therapy].
abstract: Tumor angiogenesis is one of the most important fields of cancer research. It is important to identify the putative targets for antiangiogenic strategies. To date, a number of angiogenic agents have been identified: bFGF, the different VEGF isoforms, integrins, proteases (matrix metalloproteases and serine proteases),... Furthermore, several physiological anti-angiogenic agents have been isolated such as endostatin, angiostatin, 16 K prolactin,.... The recent development of mice deficient for one gene involved during angiogenesis gives a new insight into the molecular mechanisms regulating this process. It leads to the identification of plasminogen activator inhibitor-1 or PAI-1 as a new target for tumor treatment. Although, PAI-1 is very attractive as a target for new therapeutic strategies, a better understanding of its mechanism of action is needed urgently.
authors.affiliation: Laboratoire de Biologie des Tumeurs et du Développement, CHU, Sart-Tilman, Liège, Belgique.
authors.forename: A
authors.initials: A
authors.lastname: Noël
authors.forename: J M
authors.initials: JM
authors.lastname: Foidart
mesh_terms: D009389:Neovascularization, Pathologic / Q000473:pathology / Q000517:prevention & control*; D010960:Plasminogen Activators / Q000037:antagonists & inhibitors
chemical_list: D010960:Plasminogen Activators